explore -WSS

explore

author：comprehensive 2025-10-01 00:05:46 - browse：2151

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Lilly’s obesity pill cuts 15% of weight at highest dose in mid

hotspot

WSS

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Here's how to stay safe from wildfire smoke amid reduced air quality

How to keep neuroscience’s past racism from being its future

Prime Medicine, Myeloid Therapeutics clash over genome

ADA: All diabetes patients should be screened for liver condition

Wikipedia

explore

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Medical experts exlpore how to eliminate bias in clinical algorithms

Anesthesiologist group: stop taking Ozempic before surgery

Brazil's Jair Bolsonaro is barred from running for office until 2030

Trump demands the U.S. pay no more for drugs than other countries … again

Medical experts exlpore how to eliminate bias in clinical algorithms

Apple is now the first public company to be valued at $3 trillion

GOP inquiry over gain

Anesthesiologist group: stop taking Ozempic before surgery

Prime Medicine, Myeloid Therapeutics clash over genome

explore

Tuskegee Airman Raymond Cassagnol dies at 102

Synthetic human embryos? Researchers say term is overblown

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Here's how to stay safe from wildfire smoke amid reduced air quality

Medicare Advantage beneficiaries sue Humana over algorithm use

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

focus

hotspot

hotspot

knowledge